Subcutaneous phytonadione for reversal of warfarin-induced elevation of the international normalized ratio

American Journal of Health-System Pharmacy

Volumn 56, Issue 22, 1999, Pages 2312-2315

  Byrd, Debbie C ^a,b   Stephens, Mark A ^c   Hamann, Gale L ^c   Dorko, Craig ^d  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

^c Regional Medical Center Memphis   (United States)

^d UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Anticoagulants; Dosage; Phytonadione; Toxicity; Vitamins; Warfarin

Indexed keywords

PHYTOMENADIONE; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTERNATIONAL STANDARD UNIT; MALE; OUTPATIENT; PATIENT SELECTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT INDICATION;

EID: 0033571038     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.22.2312     Document Type: Article

References (17)

1. Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med. 1989; 87:153-9.
2. Levine MN, Raskob G, Landefeld S et al. Hemorrhagic complications of anticoagulant treatment. Chest. 1995; 108:276S-90S.
3. Hirsh J, Dalen JE, Deykin D et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1992; 102:312S-26S.
4. Martinez-Abad M, Delgado F, Palop V et al. Vitamin K, and anaphylactic shock. Ann Pharmacother. 1991; 25:871-2.
5. Rich EC, Drage CW. Severe complications of intravenous phytonadione therapy. Postgrad Med J. 1982; 72:303-6.
6. Hirsh J, Dalen JE, Deykin D et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1995; 108:2315-465.
7. 1. Thromb Haemost. 1992; 67:13-5.
8. 1 in oral anticoagulant reversal. Br Med J. 1976; 2:83-5.
9. 1 therapy in excessively anticoagulated patients: a dose-finding study. J Thromb Thrombolysis. 1997; 4:289-92.
10. Crowther MA, Donovan D, Harrison L et al. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost. 1998; 79:1116-8.
11. 1. Ann Intern Med. 1997; 125:959-62.
12. 1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis. 1993; 4:739-41.
13. Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anti-coagulation. Arch Intern Med. 1998; 158:2136-40.
14. 1. J Clin Pharmacol, 1997; 37:751-7.
15. Glover JJ, Morrill GB. Conservative treatment of overanticoagulated patients. Chest. 1995; 108:987-90.
16. Lousberg TR, Witt DM, Beall DG et al. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med. 1998; 158:528-34.
17. Hirsh J, Dalen JE, Anderson DR et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998; 114:4455-695.